First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

被引：0

作者：

Sonneveld, P. ^{[1
,2
]}

van der Holt, B.

Schmidt-Wolf, I. G. H.

Bertsch, U. ^{[3
]}

el Jarari, L.

Salwender, Hans-Juergen

Zweegman, S. ^{[1
]}

Vellenga, E. ^{[1
]}

Schubert, J.

Blau, I. W.

Jie, G. S. K. ^{[1
]}

Beverloo, B. ^{[1
]}

Jauch, A. ^{[3
]}

Hose, D. ^{[3
]}

Schaafsma, R. ^{[1
]}

Kersten, M. J. ^{[1
]}

Delforge, M.

de Weerdt, O. ^{[1
]}

van der Griend, R. ^{[1
]}

Wijermans, R. W. ^{[1
]}

Martin, Hans

van der Velde, H.

Lokhorst, Henk M. ^{[1
]}

Goldschmidt, H. ^{[3
]}

机构：

[1] HOVON, Rotterdam, Netherlands

[2] Erasmus MC, Rotterdam, Netherlands

[3] Univ Heidelberg, GMMG, D-6900 Heidelberg, Germany

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：243 / 244

页数：2

共 36 条

[1] FIRST ANALYSIS OF HOVON-65/GMMG-HD4 RANDOMIZED PHASE III TRIAL COMPARING BORTEZOMIB, ADRIAMYCINE, DEXAMETHASONE (PAD) VS VAD AS INDUCTION TREATMENT PRIOR TO HIGH DOSE MELPHALAN (HDM) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
Sonneveld, P.
van der Holt, B.
Schmidt-Wolf, I. G. H.
Bertsch, U.
El Jarari, L.
Salwender, H.
Zweegman, S.
Vallenga, E.
Schubert, J.
Blau, I. W.
Jie, G. S. K.
Beverloo, B.
Jauch, A.
Hose, D.
Schaafsma, R.
Kersten, M. J.
Delforge, M.
Raymakers, R. A.
De Weerdt, O.
Van der Griend, R.
Weijermans, P. W.
Martin, H.
Van der Velde, H.
Lokhorst, H. M.
Goldschmidt, H.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 191 - 191
[2] First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
Sonneveld, P.
Eljarari, L.
Salwender, H.
Zweegman, S.
Vellenga, E.
Van der Holt, B.
Schmidt-Wolf, I. G. H.
Bertsch, U.
Schubert, J.
Blau, I. W.
Jie, G. S. K.
Beverloo, B.
Jauch, A.
Hose, D.
Schaafsma, R.
Kersten, M. J.
Delforge, M.
De Weerdt, O.
Van der Griend, R.
Wijermans, P. W.
Martin, H.
Van der Velde, H.
Lokhorst, H. M.
Goldschmidt, H.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S105 - S106
[3] HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
Sonn-Eveld, Pieter
Schmidt-Wolf, Ingo
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Schubert, Joerg
Blau, Igor Wolfgang
Jie, Asiong
Beverloo, Berna
Hose, Dirk
Jauch, Anna
van de Velde, Helgi
Schaafsma, Martijn
Lindemann, Walter
Kersten, Marie Jose
Duehrsen, Ulrich
Delforge, Michel
Weisel, Katja
Croockewit, Sandra
Martin, Hans
Wittebol, Shulamit
Scheid, Christof
Bos, Gerard
van Marwijk-Kooy, Marinus
Wijermans, Pierre
Lokhorst, Henk
Goldschmidt, Hartmut
BLOOD, 2010, 116 (21) : 23 - 24
[4] Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin , Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma
Scheid, Christof
Sonneveld, Pieter
Schmidt-Wolf, Ingo
van der Holt, Bronno
Hielscher, Thomas
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Haenel, Mathias
Vellenga, Edo
Schubert, Joerg
Blau, Igor Wolfgang
Jie, Asiong
van de Velde, Helgi
Peter, Norma
Schaafsma, Martijn
Lindemann, Walter
Kersten, Marie Jose
Duehrsen, Ulrich
Delforge, Michel
Weisel, Katja
Croockewit, Sandra
Martin, Hans
Wittebol, Shularmit
Schouten, Harry
van Marwijk-Kooy, Marinus
Wijermans, Pierre
Lokhorst, Henk M.
Goldschmidt, Hartmut
BLOOD, 2010, 116 (21) : 993 - 994
[5] Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Schmidt-Wolf, Ingo G. H.
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Broyl, Annemiek
Blau, Igor W.
Weisel, Katja C.
Wittebol, Shulamiet
Bos, Gerard M. J.
Stevens-Kroef, Marian
Scheid, Christof
Pfreundschuh, Michael
Hose, Dirk
Jauch, Anna
van der Velde, Helgi
Raymakers, Reinier
Schaafsma, Martijn R.
Kersten, Marie-Jose
van Marwijk-Kooy, Marinus
Duehrsen, Ulrich
Lindemann, Walter
Wijermans, Pierre W.
Lokhorst, Henk M.
Goldschmidt, Hartmut M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 2946 - 2955
[6] Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial (vol 30, pg 2946, 2012)
Sonneveld, P.
Schmidt-Wolf, I. G. H.
van der Hold, B.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3654 - 3654
[7] Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Scheid, Christof
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Broyl, Annemiek
Blau, Igor Wolfgang
Weisel, Katja
Wittebol, Shulamit
Bos, Gerard M. J.
Stevens, Marjan
Schmidt-Wolf, Ingo G. H.
Pfreundschuh, Michael
Hose, Dirk
Jauch, Anna
van de Velde, Helgi
Raymakers, Reinier
Schaafsma, Martyn Ronald
Kersten, Marie Jose
Kooy, Marinus van Marwijk
Duehrsen, Ulrich
Lindemann, Hans Walter
Wijermans, Pierre W.
Lokhorst, Henk
Goldschmidt, H.
BLOOD, 2013, 122 (21)
[8] Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Salwender, Hans-Juergen
Van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Blau, Igor W.
Zweegman, Sonja
Weisel, Katja C.
Vellenga, Edo
Pfreundschuh, Michael
Broijl, Annemiek
Scheid, Christof
Wittebol, Shulamiet
Bos, Gerard M. J.
Stevens-Kroef, Marjan
Jauch, Anna
Potamianou, Anna
Hose, Dirk
Raymakers, Reinier
Schaafsme, Marinus
Kersten, Marie Jose
Kooy, Marinus van Marwijk
Duehrsen, Ulrich
Lindemann, Hans Walter
Brossart, Peter
Wijermans, Pierre
Lokhorst, Henk M.
Goldschmidt, Hartmut
BLOOD, 2015, 126 (23)
[9] Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Broyl, Annemiek
Corthals, Sophie L.
Jongen, Joost L. M.
van der Holt, Bronno
Kuiper, Rowan
de Knegt, Yvonne
van Duin, Mark
el Jarari, Laila
Bertsch, Uta
Lokhorst, Henk M.
Durie, Brian G.
Goldschmidt, Hartmut
Sonneveld, Pieter
LANCET ONCOLOGY, 2010, 11 (11): : 1057 - 1065
[10] Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H Goldschmidt
H M Lokhorst
E K Mai
B van der Holt
I W Blau
S Zweegman
K C Weisel
E Vellenga
M Pfreundschuh
M J Kersten
C Scheid
S Croockewit
R Raymakers
D Hose
A Potamianou
A Jauch
J Hillengass
M Stevens-Kroef
M S Raab
A Broijl
H W Lindemann
G M J Bos
P Brossart
M van Marwijk Kooy
P Ypma
U Duehrsen
R M Schaafsma
U Bertsch
T Hielscher
Le Jarari
H J Salwender
P Sonneveld
Leukemia, 2018, 32 : 383 - 390

← 1 2 3 4 →